Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class
- 22 July 2010
- journal article
- review article
- Published by Elsevier BV in Bone
- Vol. 48 (1), 71-79
- https://doi.org/10.1016/j.bone.2010.07.016
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialThe Lancet Oncology, 2010
- The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBritish Journal of Cancer, 2010
- Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interactionBritish Journal of Cancer, 2010
- Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cellsInternational Journal of Cancer, 2009
- The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclastsBone, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBritish Journal of Haematology, 2008
- Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Bisphosphonates target multiple sites in both cis - and trans -prenyltransferasesProceedings of the National Academy of Sciences, 2007
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences, 2006